flumetasone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 4548 2135-17-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • flumetasone
  • flucorticin
  • flumethason
  • fluorodexamethazone
  • flumethasone
An anti-inflammatory glucocorticoid used in veterinary practice.
  • Molecular weight: 410.46
  • Formula: C22H28F2O5
  • CLOGP: 1.83
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 94.83
  • ALOGS: -3.68
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.942 High 0.86
caco2-efflux Caco-2 efflux ratio (BA/AB) 4.036 High 0.86
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 25.527 10^-6 cm/s High 0.86
dh-clint Dog hepatocyte intrinsic clearance 5.689 uL/min/10^6 cells High 0.86
dppb Dog plasma protein binding (% unbound) 37.820 % High 0.86
fcs-ppb Fetal calf serum protein binding (% unbound) 46.320 % High 0.86
herg hERG pIC50 4.396 pIC50 High 0.86
hh-clint Human hepatocyte intrinsic clearance 2.099 uL/min/10^6 cells High 0.86
hlm-clint Human liver microsomal intrinsic clearance 9.290 uL/min/mg protein High 0.86
hppb Human plasma protein binding (% unbound) 25.310 % High 0.86
kinase-safety-class ACVR2B,CDK5,EIF2AK3,GRK2,ITK,MAPK10,PDK1,PDK2,PDK4,PRKDC 10
kinase-selectivity-class GRK2,MAP2K6,PDK1 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 13.305 Moderate 0.71
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 8.590 High 0.86
mh-clint Mouse hepatocyte intrinsic clearance 16.106 High 0.86
mppb Mouse plasma protein binding (% unbound) 36.050 High 0.86
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 17.219 High 0.86
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.71
pppb Pig plasma protein binding (% unbound) 37.760 % High 0.86
rat-kpuu-brain Rat brain Kpuu 0.070 % Moderate 0.71
rh-clint Rat hepatocyte intrinsic clearance 24.434 uL/min/10^6 cells High 0.86
rh-fuinc Rat hepatocyte fraction unbound in incubation 75.930 % High 0.86
rppb Rat plasma protein binding (% unbound) 24.920 % High 0.86
solubility-dd Solubility at pH 7.4 in DMSO 417.830 uM High 0.86

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product label confusion 406.08 98.54 189 33547 22661 90572050
Blepharospasm 355.50 98.54 234 33502 55211 90539500
Grip strength decreased 350.39 98.54 284 33452 92292 90502419
Finger deformity 335.45 98.54 187 33549 32710 90562001
Coeliac disease 329.87 98.54 206 33530 44404 90550307
Adverse reaction 325.26 98.54 177 33559 29535 90565176
Back injury 324.01 98.54 207 33529 46415 90548296
Nail disorder 323.20 98.54 226 33510 58841 90535870
Breast cancer stage III 308.88 98.54 254 33482 84193 90510518
Epilepsy 285.56 98.54 240 33496 81966 90512745
Taste disorder 267.65 98.54 205 33531 61341 90533370
Bursitis 266.58 98.54 285 33451 131369 90463342
Facet joint syndrome 263.64 98.54 248 33488 98141 90496570
Onychomycosis 247.46 98.54 161 33575 37215 90557496
Onychomadesis 246.94 98.54 174 33562 45824 90548887
Injury 238.70 98.54 329 33407 197020 90397691
Drug-induced liver injury 236.88 98.54 225 33511 90093 90504618
Dyspepsia 230.18 98.54 324 33412 197836 90396875
Hypercholesterolaemia 228.57 98.54 232 33504 100660 90494051
Hepatitis 222.19 98.54 195 33541 70544 90524167
Peripheral venous disease 218.04 98.54 208 33528 83713 90510998
Liver injury 217.81 98.54 292 33444 170275 90424436
Live birth 214.95 98.54 201 33535 78906 90515805
Gastrooesophageal reflux disease 205.14 98.54 280 33456 166057 90428654
Mobility decreased 204.27 98.54 348 33388 250386 90344325
Blood cholesterol increased 203.87 98.54 314 33422 207698 90387013
Product quality issue 203.03 98.54 195 33541 79130 90515581
Liver function test increased 199.28 98.54 199 33537 84656 90510055
Wound infection 197.31 98.54 220 33516 106182 90488529
Lip dry 194.55 98.54 213 33523 100742 90493969
Folliculitis 187.08 98.54 299 33437 204054 90390657
Migraine 178.99 98.54 282 33454 190110 90404601
Inflammation 174.10 98.54 269 33467 178323 90416388
Abdominal distension 173.45 98.54 228 33508 130373 90464338
Neck pain 157.61 98.54 203 33533 113760 90480951
Joint range of motion decreased 153.24 98.54 219 33517 135424 90459287
Obesity 150.72 98.54 191 33545 105316 90489395
Gait inability 143.25 98.54 221 33515 146235 90448476
Helicobacter infection 132.31 98.54 273 33463 226577 90368134
Type 2 diabetes mellitus 130.98 98.54 255 33481 202989 90391722
Hand deformity 129.62 98.54 318 33418 296044 90298667
Dry mouth 128.56 98.54 239 33497 183820 90410891
Psoriatic arthropathy 126.42 98.54 269 33467 228066 90366645
Duodenal ulcer perforation 122.85 98.54 261 33475 221027 90373684
Fibromyalgia 122.35 98.54 250 33486 206019 90388692
Injection site reaction 121.03 98.54 160 33576 91920 90502791
Anti-cyclic citrullinated peptide antibody positive 118.92 98.54 268 33468 236165 90358546
C-reactive protein increased 114.92 98.54 226 33510 181163 90413548
Ulcer haemorrhage 112.87 98.54 87 33649 26234 90568477
Glossodynia 107.99 98.54 313 33423 321466 90273245
Drug ineffective 107.65 98.54 222 33514 1384076 89210635
Hypoaesthesia 106.75 98.54 307 33429 313903 90280808
Pericarditis 106.74 98.54 279 33457 269872 90324839
Pruritus 103.97 98.54 36 33700 541489 90053222
Pemphigus 100.25 98.54 308 33428 326556 90268155
Sleep disorder 100.13 98.54 225 33511 197805 90396906
Night sweats 99.80 98.54 175 33561 128591 90466120
Intentional product use issue 99.32 98.54 237 33499 216655 90378056

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product label confusion 456.41 154.34 190 31841 22487 110534781
Grip strength decreased 451.39 154.34 284 31747 79890 110477378
Blepharospasm 390.62 154.34 226 31805 54625 110502643
Coeliac disease 387.00 154.34 207 31824 42980 110514288
Finger deformity 381.62 154.34 188 31843 32904 110524364
Adverse reaction 370.95 154.34 178 31853 29416 110527852
Breast cancer stage III 368.74 154.34 249 31782 78868 110478400
Nail disorder 363.58 154.34 220 31811 57715 110499553
Back injury 355.42 154.34 202 31829 47197 110510071
Bursitis 322.53 154.34 281 31750 129637 110427631
Facet joint syndrome 308.30 154.34 242 31789 96586 110460682
Hypercholesterolaemia 295.63 154.34 230 31801 90607 110466661
Taste disorder 283.81 154.34 197 31834 65190 110492078
Blood cholesterol increased 283.79 154.34 307 31724 184478 110372790
Folliculitis 283.13 154.34 293 31738 167360 110389908
Onychomycosis 282.91 154.34 162 31869 38369 110518899
Epilepsy 281.99 154.34 233 31798 99976 110457292
Onychomadesis 270.08 154.34 167 31864 45496 110511772
Hand deformity 258.05 154.34 317 31714 218189 110339079
Wound infection 254.26 154.34 216 31815 96249 110461019
Injury 247.12 154.34 280 31751 176985 110380283
Glossodynia 244.46 154.34 311 31720 221693 110335575
Product quality issue 243.43 154.34 192 31839 77107 110480161
Gastrooesophageal reflux disease 241.96 154.34 279 31752 179697 110377571
Live birth 241.51 154.34 183 31848 69301 110487967
Liver injury 236.31 154.34 253 31778 150160 110407108
Dyspepsia 235.11 154.34 283 31748 190682 110366586
Drug-induced liver injury 232.33 154.34 226 31805 119841 110437427
Peripheral venous disease 227.10 154.34 191 31840 83926 110473342
Mobility decreased 226.49 154.34 310 31721 237112 110320156
Helicobacter infection 226.30 154.34 271 31760 181606 110375662
Hepatitis 225.83 154.34 196 31835 89858 110467410
Liver function test increased 216.56 154.34 190 31841 88358 110468910
Anti-cyclic citrullinated peptide antibody positive 211.53 154.34 262 31769 181722 110375546
Lip dry 208.03 154.34 196 31835 99887 110457381
Duodenal ulcer perforation 205.19 154.34 255 31776 177445 110379823
Fibromyalgia 193.71 154.34 243 31788 170666 110386602
Migraine 192.87 154.34 243 31788 171409 110385859
Gait inability 189.27 154.34 215 31816 136161 110421107
Joint range of motion decreased 184.41 154.34 201 31830 121631 110435637
Inflammation 182.23 154.34 251 31780 192987 110364281
Pemphigus 176.30 154.34 261 31770 214309 110342959
Neck pain 175.76 154.34 197 31834 122933 110434335
Obesity 175.03 154.34 189 31842 113162 110444106
Type 2 diabetes mellitus 174.35 154.34 235 31796 176997 110380271
Arthropathy 171.08 154.34 302 31729 287220 110270048
Psoriatic arthropathy 169.85 154.34 245 31786 196516 110360752
Abdominal distension 167.42 154.34 229 31802 174874 110382394
Acute kidney injury 165.24 154.34 4 32027 635426 109921842
Pericarditis 162.30 154.34 254 31777 218860 110338408
Injection site reaction 158.06 154.34 160 31871 88910 110468358

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D07AB03 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, moderately potent (group II)
ATC D07BB01 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS
Corticosteroids, moderately potent, combinations with antiseptics
ATC D07CB05 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
Corticosteroids, moderately potent, combinations with antibiotics
ATC D07XB01 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, OTHER COMBINATIONS
Corticosteroids, moderately potent, other combinations
ATC S02CA02 SENSORY ORGANS
OTOLOGICALS
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
Corticosteroids and antiinfectives in combination
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
CHEBI has role CHEBI:35472 anti-inflammatory drug

Related Drugs by ATC class:

D07AB Corticosteroids, moderately potent (group II) 12 drugs
alclometasone dipropionateclobetasone butyrateclocortolone pivalatedesonidedexamethasonefluocortin butylfluorometholonefluperolonefluprednidenehydrocortisone butyratehydrocortisone probutatetriamcinolone
D07BB Corticosteroids, moderately potent, combinations with antiseptics 3 drugs
desonidehydrocortisone butyratetriamcinolone
D07CB Corticosteroids, moderately potent, combinations with antibiotics 4 drugs
dexamethasonefluorometholonefluprednidenetriamcinolone
D07XB Corticosteroids, moderately potent, other combinations 4 drugs
dexamethasonefluorometholonefluprednidenetriamcinolone
S02CA Corticosteroids and antiinfectives in combination 6 drugs
dexamethasonefludrocortisone acetatefluocinolone acetonidehydrocortisoneprednisolonetriamcinolone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Hypopituitarism contraindication 74728003 DOID:9406
Skin striae contraindication 201066002
Telangiectasia disorder contraindication 247479008
Atrophoderma contraindication 399979006




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Acute and chronic dermatoses of varying etiology Indication
Dogs Musculoskeletal conditions caused by inflammation of muscles or joints and accessory structures where permanent structural changes do not exist Indication
Dogs Acute and chronic dermatoses of varying etiology Indication
Dogs Otitis externa in conjunction with topical medication Indication
Dogs Allergic states Indication
Dogs Shock and shock-like states Indication
Horse Musculoskeletal conditions caused by inflammation, where permanent structural changes do not exist Indication
Horse Allergic states Indication

🐶 Veterinary products

ProductApplicantIngredients
Flucort Solution Zoetis Inc. 1
Flucort Tablets Zoetis Inc. 1
Anaprime Suspension Zoetis Inc. 1
Anaprime Ophthalmic Solution Zoetis Inc. 3
Anaprime Opthakote Ophthalmic Zoetis Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.06 acidic
pKa2 12.45 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D04208 KEGG_DRUG
N0000167461 NUI
CHEBI:34764 CHEBI
CHEMBL1201392 ChEMBL_ID
DB00663 DRUGBANK_ID
4458 RXNORM
004949 NDDF
116598007 SNOMEDCT_US
3037004 SNOMEDCT_US
C0016294 UMLSCUI
D005443 MESH_DESCRIPTOR_UI
16490 PUBCHEM_CID
1355 INN_ID
LR3CD8SX89 UNII
LR3CD8SX89 INXIGHT DRUGS

Pharmaceutical products:

None